News & Updates

Durable vision outcomes and extended Tx interval with aflibercept 8 mg in nAMD and DME: Insights for clinical practice

23 Apr 2025 by

Anti-vascular endothelial growth factor (anti-VEGF) agents are considered the standard of care (SoC) for neovascular agerelated macular degeneration (nAMD) and diabetic macular oedema (DME). However, the need for frequent intravitreal (IVT) injections leads to a substantial treatment burden. In an interview with MIMS Doctor, Professor Michael Stewart of the Mayo Clinic in Jacksonville, Florida, US, discussed how the highdose formulation of the anti-VEGF agent, aflibercept 8 mg, may address challenges associated with nAMD and DME management based on results of the pivotal PULSAR and PHOTON trials as well as his patients’ early experience.

Durable vision outcomes and extended Tx interval with aflibercept 8 mg in nAMD and DME: Insights for clinical practice

23 Apr 2025

VEGF inhibitor high-dose formulation sustains disease control, extends treatment interval in nAMD

21 Mar 2025 by

An 89-year-old male with bilateral (OU) pseudophakia and primary open-angle glaucoma (POAG) was being monitored for neovascular age-related macular degeneration (nAMD) in the left eye (OS). He used an Amsler grid to monitor his visual function.

VEGF inhibitor high-dose formulation sustains disease control, extends treatment interval in nAMD

21 Mar 2025

Maximizing outcomes in nAMD and PCV with a multitargeted VEGF inhibitor

17 Oct 2024 by

The anti–vascular endothelial growth factor (anti-VEGF), aflibercept, has demonstrated durable visual improvements in patients with various exudative retinal diseases. At a Bayer-sponsored symposium during the 16th Congress of the Asia-Pacific Vitreo-Retina Society, Professor Michael Stewart of the Mayo Clinic in Jacksonville, Florida, US, and Professor Voraporn Chaikitmongkol of Chiang Mai University in Chiang Mai, Thailand, shared real-world experiences supporting the role of aflibercept in management of neovascular age-related macular degeneration (nAMD) and polypoidal choroidal vasculopathy (PCV).

Maximizing outcomes in nAMD and PCV with a multitargeted VEGF inhibitor

17 Oct 2024

Achieving optimal outcomes in DME with a VEGF inhibitor

15 Aug 2024 by

Anti–vascular endothelial growth factor (anti-VEGF) therapy is the primary recommended treatment for patients with diabetic macular oedema (DME). At a Bayer-sponsored symposium during the 16^th Congress of the Asia-Pacific Vitreo-Retina Society, experts in ophthalmology discussed clinical and real-world data on aflibercept, shared their personal experience of using it for DME treatment and highlighted its advantages vs other available anti-VEGF agents.

Achieving optimal outcomes in DME with a VEGF inhibitor

15 Aug 2024

No increased ophthalmic risk with roxadustat treatment in DD CKD-related anaemia

28 Jun 2020 by

Roxadustat treatment for anaemia in patients with dialysis-dependent chronic kidney disease (DD CKD) does not come with an increased risk of ophthalmic abnormalities, according to a phase III trial conducted in Japan.

No increased ophthalmic risk with roxadustat treatment in DD CKD-related anaemia

28 Jun 2020

News & Updates

Filter by Specialty:

Specialty:

Durable vision outcomes and extended Tx interval with aflibercept 8 mg in nAMD and DME: Insights for clinical practice

Durable vision outcomes and extended Tx interval with aflibercept 8 mg in nAMD and DME: Insights for clinical practice

VEGF inhibitor high-dose formulation sustains disease control, extends treatment interval in nAMD

VEGF inhibitor high-dose formulation sustains disease control, extends treatment interval in nAMD

Maximizing outcomes in nAMD and PCV with a multitargeted VEGF inhibitor

Maximizing outcomes in nAMD and PCV with a multitargeted VEGF inhibitor

Achieving optimal outcomes in DME with a VEGF inhibitor

Achieving optimal outcomes in DME with a VEGF inhibitor

No increased ophthalmic risk with roxadustat treatment in DD CKD-related anaemia

No increased ophthalmic risk with roxadustat treatment in DD CKD-related anaemia